- Home
- ATOS vs SRZN Comparison
ATOS vs SRZN Comparison
Compare ATOS & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- SRZN
- Stock Information
- Founded
- ATOS 2009
- SRZN 2015
- Country
- ATOS United States
- SRZN United States
- Employees
- ATOS N/A
- SRZN N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- ATOS Health Care
- SRZN Health Care
- Exchange
- ATOS Nasdaq
- SRZN Nasdaq
- Market Cap
- ATOS 107.2M
- SRZN 97.3M
- IPO Year
- ATOS 2012
- SRZN N/A
- Fundamental
- Price
- ATOS $0.84
- SRZN $11.45
- Analyst Decision
- ATOS Strong Buy
- SRZN Strong Buy
- Analyst Count
- ATOS 3
- SRZN 2
- Target Price
- ATOS $6.17
- SRZN $38.50
- AVG Volume (30 Days)
- ATOS 483.0K
- SRZN 12.2K
- Earning Date
- ATOS 11-11-2025
- SRZN 11-05-2025
- Dividend Yield
- ATOS N/A
- SRZN N/A
- EPS Growth
- ATOS N/A
- SRZN N/A
- EPS
- ATOS N/A
- SRZN N/A
- Revenue
- ATOS N/A
- SRZN $12,621,000.00
- Revenue This Year
- ATOS N/A
- SRZN N/A
- Revenue Next Year
- ATOS N/A
- SRZN N/A
- P/E Ratio
- ATOS N/A
- SRZN N/A
- Revenue Growth
- ATOS N/A
- SRZN N/A
- 52 Week Low
- ATOS $0.55
- SRZN $5.90
- 52 Week High
- ATOS $1.66
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- SRZN 52.78
- Support Level
- ATOS $0.81
- SRZN $11.36
- Resistance Level
- ATOS $0.80
- SRZN $12.11
- Average True Range (ATR)
- ATOS 0.03
- SRZN 0.69
- MACD
- ATOS 0.01
- SRZN -0.13
- Stochastic Oscillator
- ATOS 92.67
- SRZN 27.07
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).